ArticleHealthcare (Basel, Switzerland)2026
Economic Factors Associated with AI Adoption in Oncology: Cost-Effectiveness Perceptions, Reimbursement Readiness, and Return-on-Investment Confidence Among Romanian Healthcare Professionals.
Article in Healthcare (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesArtificial intelligence (AI) tools promise efficiency gains in oncology, yet adoption depends on economic factors that remain under-characterized in Eastern European health systems. We quantified AI economic literacy, cost-effectiveness perceptions, reimbursement readiness, and return-on-investment (ROI) confidence among Romanian oncology professionals; we described candidate economic adoption profiles and examined whether sector was associated with the strength of the indirect association between literacy and willingness to invest via ROI confidence. MATERIALS AND
methodsA multicenter cross-sectional survey (
resultsMean age was 41.3 ± 10.7 years; 58.3% were female. AIELI was moderate (13.7 ± 4.6/25). Familiarity favored cost-effectiveness analysis (59.3%) over AI-specific reimbursement codes (16.7%). High willingness to invest occurred in 48.1% and was independently associated with higher AIELI (aOR 1.78 per +1 SD; 95% CI 1.17-2.71), higher ROI confidence (aOR 1.93; 1.24-3.02), lower perceived financial barriers (aOR 0.58; 0.37-0.91), and prior AI training (aOR 2.34; 1.13-4.86). Three exploratory profiles were identified: Cost-Conscious Adopters (
conclusionsIn this exploratory cross-sectional sample, AI economic literacy and ROI confidence were associated with willingness to invest in oncology AI, interpreted as stated support for investment rather than an enacted procurement decision, since many respondents lacked formal budgetary authority. Because the design cannot establish temporal ordering, whether sector-tailored capability-building and reimbursement clarity would increase adoption remains a hypothesis for prospective evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.